Professor Marek Trněný is a Professor of Medical Oncology and Head of the First Faculty of Medicine at Charles University Hospital, Prague, CZ. He graduated from the Faculty of General Medicine at Charles University, Prague, CZ, in 1985, and until 1989 he worked at the Institute of Chemical Technology, Prague, CZ. Since 1990, Prof. Trněný has worked at the General Teaching Hospital and the First Faculty of Medicine and has completed his residency and fellowship in internal medicine, hematology, and medical oncology. In January 2008, he was appointed Head of the First Internal Clinic of the General Teaching Hospital and First Faculty of Medicine at Charles University, and he was appointed as Professor of Medical Oncology in 2009.

Prof. Trněný’s professional focus is on the pathogenesis and targeted treatment of lymphoma and chronic lymphocytic leukemia, including hematopoietic stem cell transplantation. He has authored and co-authored more than 170 research papers and reviews, and has participated either as principal investigator or sub-investigator in more than 30 clinical trials within the field of hematology.

He graduated from the Faculty of General Medicine at Charles University, Prague, CZ, in 1985, and until 1989 he worked at the Institute of Chemical Technology, Prague, CZ. Since 1990, Prof. Trněný has worked at the General Teaching Hospital and the First Faculty of Medicine and has completed his residency and fellowship in internal medicine, hematology, and medical oncology. In January 2008, he was appointed Head of the First Internal Clinic of the General Teaching Hospital and First Faculty of Medicine at Charles University, and he was appointed as Professor of Medical Oncology in 2009.

Prof. Trněný’s professional focus is on the pathogenesis and targeted treatment of lymphoma and chronic lymphocytic leukemia, including hematopoietic stem cell transplantation. He has authored and co-authored more than 170 research papers and reviews, and has participated either as principal investigator or sub-investigator in more than 30 clinical trials within the field of hematology.